Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.